3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
4
NIH
1
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Melanoma
7
Colorectal Neoplasms
7
Carcinoma, Renal Cell
7
Neoplasms
6
Lymphoma, Non-Hodgkin
6
Carcinoma, Non-Small-Cell Lung
6
Uterine Cervical Neoplasms
4
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Lymphoma
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Carcinoma, Merkel Cell
4
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Head and Neck Neoplasms
3
Carcinoma, Transitional Cell
3
Small Cell Lung Carcinoma
2
Skin Neoplasms
2
Lymphoma, Follicular
2
Lymphoma, B-Cell
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Hematologic Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Interventions
Brentuximab Vedotin
27
pembrolizumab
13
Nivolumab
11
Dacarbazine
8
Vinblastine
7
Doxorubicin
7
Gemcitabine
6
Bendamustine Hydrochloride
6
plerixafor
5
fludarabine
4
Rituximab
4
Granulocyte Colony-Stimulating Factor
4
Cyclophosphamide
4
Azacitidine
4
abexinostat
3
Melphalan
3
Filgrastim
3
Etoposide
3
Busulfan
3
Bleomycin
3
umbralisib
2
relatlimab
2
pegfilgrastim
2
mocetinostat
2
itacitinib
2
givinostat hydrochloride
2
givinostat
2
fludarabine phosphate
2
durvalumab
2
cc-486
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hodgkin Disease
×
Interleukin-2
×
Clear all
NCT05883449
2025-08-20
LuminICE-203
Affimed GmbH
Phase 2
Terminated
25 enrolled
21 charts